Livzon Pharma Unit's Plaque Psoriasis Drug Granted Priority Review in China

MT Newswires Live

01/07

Livzon Pharmaceutical Group (HKG:1513, SHE:000513) said the Lecankitug Injection was included in the public list of drugs proposed for priority review by China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.

The drug, jointly developed by Livzon MABPharm, a controlling subsidiary of the company, and Beijing Xinkanghe Biopharmaceutical Technology, has now entered the priority review and approval process for marketing authorization.

The drug is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2601803050"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2601803050\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2601803050?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-07 21:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601803050","market":"fut","top_or_hot":-1,"title":"Livzon Pharma Unit's Plaque Psoriasis Drug Granted Priority Review in China","media":"MT Newswires Live","content":"<html><body><p> Livzon Pharmaceutical Group (HKG:1513, SHE:000513) said the Lecankitug Injection was included in the public list of drugs proposed for priority review by China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.</p><p>The drug, jointly developed by Livzon MABPharm, a controlling subsidiary of the company, and Beijing Xinkanghe Biopharmaceutical Technology, has now entered the priority review and approval process for marketing authorization.</p><p>The drug is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Livzon Pharma Unit's Plaque Psoriasis Drug Granted Priority Review in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLivzon Pharma Unit's Plaque Psoriasis Drug Granted Priority Review in China\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-01-07 21:12</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Livzon Pharmaceutical Group (HKG:1513, SHE:000513) said the Lecankitug Injection was included in the public list of drugs proposed for priority review by China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.</p><p>The drug, jointly developed by Livzon MABPharm, a controlling subsidiary of the company, and Beijing Xinkanghe Biopharmaceutical Technology, has now entered the priority review and approval process for marketing authorization.</p><p>The drug is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"國家隊","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2601803050","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601803050","pubTimestamp":1767791551,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Livzon Pharmaceutical Group  said the Lecankitug Injection was included in the public list of drugs proposed for priority review by China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.The drug, jointly developed by Livzon MABPharm, a controlling subsidiary of the company, and Beijing Xinkanghe Biopharmaceutical Technology, has now entered the priority review and approval process for marketing authorization.The drug is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0028":"国家队","BK0239":"医药制造","01513":"丽珠医药","000513":"丽珠集团","BK1191":"制药","BK0188":"融资融券","BK0187":"一线龙头"},"translate_title":"丽珠医药旗下斑块型银屑病药物获中国优先审评","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000513":0.9,"01513":0.9},"content_text":"Livzon Pharmaceutical Group (HKG:1513, SHE:000513) said the Lecankitug Injection was included in the public list of drugs proposed for priority review by China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.The drug, jointly developed by Livzon MABPharm, a controlling subsidiary of the company, and Beijing Xinkanghe Biopharmaceutical Technology, has now entered the priority review and approval process for marketing authorization.The drug is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}